ACHL Achilles Therapeutics PLC ADR

USD 1.36 0.00 0
Icon

Achilles Therapeutics PLC ADR (ACHL) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Sell

Average Analyst
Rating
stockTargetAdvisor

Sell

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.36

0.00 (0.00)%

USD 0.06B

1.95M

USD 0.50(-63.24%)

USD 6.00 (+341.18%)

Icon

ACHL

Achilles Therapeutics PLC ADR (USD)
COMMON STOCK | NSD
USD 1.36
0.00 0
Take a Tour
stockTargetAdvisor

Sell

Average Analyst
Rating
stockTargetAdvisor

Sell

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.06B

USD 6.00 (+341.18%)

USD 1.36

Achilles Therapeutics PLC ADR (ACHL) Stock Forecast

Show ratings and price targets of :
USD 0.50
(-63.24%)

Based on the Achilles Therapeutics PLC ADR stock forecast from 1 analysts, the average analyst target price for Achilles Therapeutics PLC ADR is USD 0.50 over the next 12 months. Achilles Therapeutics PLC ADR’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Achilles Therapeutics PLC ADR is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Achilles Therapeutics PLC ADR’s stock price was USD 1.36. Achilles Therapeutics PLC ADR’s stock price has changed by +28.30% over the past week, +49.78% over the past month and +21.43% over the last year.

No recent analyst target price found for Achilles Therapeutics PLC ADR
No recent average analyst rating found for Achilles Therapeutics PLC ADR

Company Overview Achilles Therapeutics PLC ADR

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advan...Read More

https://www.achillestx.com

245 Hammersmith Road, London, United Kingdom, W6 8PW

234

December

USD

USA

Adjusted Closing Price for Achilles Therapeutics PLC ADR (ACHL)

Loading...

Unadjusted Closing Price for Achilles Therapeutics PLC ADR (ACHL)

Loading...

Share Trading Volume for Achilles Therapeutics PLC ADR Shares

Loading...

Compare Performance of Achilles Therapeutics PLC ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACHL

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Achilles Therapeutics PLC ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD90.49B 26.38 17.57

ETFs Containing ACHL

Symbol Name ACHL's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Achilles Therapeutics PLC ADR (ACHL) Stock

Unfortunately we do not have enough data on ACHL's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ACHL is USD 0.50 over the next 12 months. The maximum analyst target price is USD 0.5 while the minimum anlayst target price is USD 0.5.

ACHL stock's Price/Earning ratio is 0.17. Our analysis grades ACHL stock's Price / Earning ratio at B. This means that ACHL stock's Price/Earning ratio is above 17% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ACHL may be undervalued for its sector.

The last closing price of ACHL's stock was USD 1.36.

The most recent market capitalization for ACHL is USD 0.06B.

Based on targets from 1 analysts, the average taret price for ACHL is projected at USD 0.50 over the next 12 months. This means that ACHL's stock price may go down by -63.24% over the next 12 months.

We can't find any ETFs which contains Achilles Therapeutics PLC ADR's stock.

As per our most recent records Achilles Therapeutics PLC ADR has 234 Employees.

Achilles Therapeutics PLC ADR's registered address is 245 Hammersmith Road, London, United Kingdom, W6 8PW. You can get more information about it from Achilles Therapeutics PLC ADR's website at https://www.achillestx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...